General
Preferred name
CDK8/19-IN-51
Synonyms
CCT251545 analogue, Compound 51 ()
compound 51 [Mallinger et al., 2016] ()
P&D ID
PD047699
CAS
1860885-61-5
Tags
available
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
1492
DESCRIPTION
Compound 51 is a potent and selective CDK8/19 inhibitor . It is one of the compounds claimed in patent WO2016009076 . Compound 51 hasa similar inhibitory potency as , but is built on a modified chemical scaffold . This is a type I inhibitor, binding in a DMG-in mode.
(GtoPdb)
DESCRIPTION
CDK8/19-IN-51 is an orally active and highly effective dual inhibitor of CDK8 and CDK19, with anticancer activity. Its IC50 values for CDK8 and CDK19 are 5.1 nM and 5.6 nM, respectively. It is used in studies of colorectal and gastric cancers.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
11
Molecular Weight
414.18
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
4
cLogP
2.75
TPSA
99.16
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CDK19；CDK8
Pathway
Cell Cycle/Checkpoint
Source data
